GMED vs ZBH
Globus Medical vs Zimmer Biomet — AI-powered side-by-side comparison
GMED
Globus Medical
70
Buy
VS
| Metric | GMED | ZBH |
|---|
| AI Score |
70
|
70
|
| Price |
$82.34
|
$96.61
|
| P/E Ratio |
20.74×
|
23.38×
|
| ROE |
11.8%
|
5.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
68.5%
|
69.9%
|
| Debt / Equity |
0.02×
|
0.59×
|
| Dividend Yield |
0.0%
|
1.0%
|
| RSI (14) |
64.2
|
58.9
|
| Beta |
0.954
|
0.468
|
| Expected Upside |
+1.8%
|
+1.2%
|
AI Committee View
Current Innellis committee reasoning for GMED versus ZBH.
The committee scores are tied.
GMED and ZBH both score 70/100.
GMED Committee View
100% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. The main limiting factor is 4 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- EPS growing 221.2% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- Both daily and weekly trends are bearish — strong multi-timeframe downtrend.
- Lower Highs / Lower Lows structure confirms bearish price action.
ZBH Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Both daily and weekly trends are bearish — strong multi-timeframe downtrend.
- Risk/reward is unfavorable: 11.2% downside vs 1.2% upside.